Tirzepatide Research Guide
Tirzepatide: Research Guide, Mechanism, Half-Life and Findings
Tirzepatide, also known as LY3298176, is a synthetic research peptide studied for its dual receptor agonist activity across the GIP and GLP-1 receptors. This guide explains what Tirzepatide is, how its dual mechanism works, its research half-life and study dosing, the findings reported across the SURPASS and SURMOUNT trial programs, how it compares to Retatrutide and Semaglutide, and what Australian researchers should look for when sourcing research-grade Tirzepatide.
What is Tirzepatide?
Tirzepatide is an investigational synthetic peptide developed by Eli Lilly and referenced in scientific literature as LY3298176. It is a 39-amino acid peptide, structurally based on the GIP sequence with a C20 fatty di-acid moiety that extends its duration of action. Tirzepatide is engineered to activate two metabolic receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Because it engages both pathways, it is described as a dual receptor agonist, or "dual agonist".
In therapeutic settings outside Australia, tirzepatide is marketed under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for weight management). As a research compound, it sits between the single-pathway GLP-1 agonists such as Semaglutide and the triple agonist Retatrutide, making it a central reference point in metabolic research.
Tirzepatide is sometimes searched as "tirz" or "tirz peptide"; these refer to the same compound (LY3298176). Australian researchers can buy Tirzepatide in Australia or browse the full peptides Australia range from Omega Peptides Australia.
How Tirzepatide Works: The Dual Agonist Mechanism
Tirzepatide is studied as a dual receptor agonist, meaning it is investigated for simultaneous activity across two receptor families that regulate metabolism and energy balance. Understanding each receptor individually explains why the compound generates so much research interest.
GLP-1 receptor
The GLP-1 (glucagon-like peptide-1) receptor is the pathway targeted by first-generation incretin compounds. In research models it is associated with appetite signalling, slowed gastric emptying, and glucose-dependent insulin regulation. This is the foundational mechanism that Tirzepatide shares with Semaglutide.
GIP receptor
The GIP (glucose-dependent insulinotropic polypeptide) receptor is studied for its role in insulin signalling, energy balance, and metabolic adaptation. Adding GIP activity to GLP-1 activity is the defining feature of Tirzepatide. Research indicates that Tirzepatide engages the GIP receptor to a greater degree than the GLP-1 receptor, an "imbalanced" mechanism of action, and shows biased signalling at the GLP-1 receptor. This combination is frequently cited as the reason dual agonism can exceed the effects of selective GLP-1 receptor agonists in research models.
| Receptor | Research Relevance |
|---|---|
| GLP-1 receptor | Studied for effects relating to appetite signalling, glucose regulation, and metabolic control. |
| GIP receptor | Studied for its role in insulin signalling, energy balance, and metabolic adaptation, with tirzepatide showing a greater degree of GIP receptor engagement. |
Because Tirzepatide interacts with two receptor systems, researchers often compare it with the single-pathway compound Semaglutide and the triple agonist Retatrutide.
Tirzepatide Development and Trial Status
Tirzepatide was developed by Eli Lilly under the code name LY3298176. Its receptor pharmacology was characterised by Coskun and colleagues in Molecular Metabolism in 2018. It then progressed through one of the largest clinical programs in metabolic research, split into two named trial series.
The SURPASS program studied Tirzepatide in type 2 diabetes across doses of 5mg, 10mg and 15mg per week, reporting dose-dependent improvements versus placebo, semaglutide 1mg, and insulin comparators. The SURMOUNT program studied Tirzepatide for weight management in obesity. In 2025, the head-to-head SURMOUNT-5 trial reported that tirzepatide produced greater weight reduction than semaglutide over 72 weeks, the first direct comparison of the two compounds.
| Study | Program / Journal | Research Focus |
|---|---|---|
| Coskun et al. (2018) | Molecular Metabolism | Characterisation of the dual GIP/GLP-1 receptor mechanism |
| SURPASS-1 to -5 (2021-2022) | Lancet, NEJM, JAMA | Type 2 diabetes, doses 5-15mg weekly |
| SURMOUNT-1 (2022) | NEJM | Obesity, 72-week body weight study |
| SURMOUNT-5 (2025) | NEJM | Head-to-head vs semaglutide over 72 weeks |
Because it is an investigational compound in this research context, Tirzepatide is not registered by the TGA for research supply and is not available through pharmacies or therapeutic channels in Australia for research use. It is supplied only by specialist research suppliers, strictly for laboratory research use.
Why Tirzepatide is a Major Research Compound
Interest in Tirzepatide has grown due to its dual receptor profile and the scale of its clinical evidence base. Its combination of GIP and GLP-1 activity makes it one of the most studied compounds in incretin research.
Key areas of research interest include:
- Dual-pathway metabolic signalling
- Energy balance and body composition research models
- Glucose and insulin-related research
- Comparison with single agonist (Semaglutide) and triple agonist (Retatrutide) compounds
- Imbalanced and biased receptor signalling
- Longer-term receptor activity and tolerance research
Tirzepatide vs Retatrutide vs Semaglutide
The clearest way to place Tirzepatide is by comparing how many receptor systems each incretin compound engages. Semaglutide (behind Ozempic and Wegovy) is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Retatrutide adds a third pathway, glucagon, making it a triple agonist. For a deeper comparison with the triple agonist, see our Retatrutide research guide.
| Compound | Primary Research Mechanism | Research Category |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Single agonist |
| Tirzepatide | GIP and GLP-1 receptor agonist | Dual agonist |
| Retatrutide | GIP, GLP-1, and glucagon receptor agonist | Triple agonist |
This single-to-dual-to-triple progression is why Tirzepatide is studied as a distinct step beyond selective GLP-1 compounds, and why it is often used as the reference point against which newer agonists are measured.
Tirzepatide Dosage in Research
Tirzepatide dosage is entirely protocol-dependent and is determined by the research design being followed. In the published clinical program, Tirzepatide was investigated using a gradual dose-escalation approach with weekly administration, with study arms of 5mg, 10mg and 15mg per week.
For laboratory reference, Omega Peptides Australia supplies Tirzepatide in 10mg and 30mg research strengths, allowing researchers to reconstitute to the concentration required by their protocol. Tirzepatide is supplied strictly for laboratory research use only, and any handling should follow the relevant institutional guidelines.
Tirzepatide Half-Life
Tirzepatide has a long research half-life, reported at approximately 5 days. This extended half-life is the reason the compound has been studied using once-weekly administration schedules in research settings, rather than daily dosing.
The lyophilised (freeze-dried) format supplied for research supports stability during storage and transport, which is particularly relevant across Australia's varied climate.
Tirzepatide Research Findings
Tirzepatide has one of the most extensive evidence bases of any incretin research compound. In the SURPASS type 2 diabetes program, it produced dose-dependent reductions in HbA1c and body weight that exceeded placebo, semaglutide 1mg and insulin comparators (Frias et al., 2021; Rosenstock et al., 2021). In the SURMOUNT-1 obesity trial published in the New England Journal of Medicine (Jastreboff et al., 2022), Tirzepatide was associated with substantial reductions in body weight over 72 weeks in the highest study arms.
More recently, the SURMOUNT-5 head-to-head trial (2025) reported that Tirzepatide produced greater weight reduction than Semaglutide over 72 weeks, the first direct comparison between a dual agonist and a leading single agonist. These findings are frequently cited as the reason Tirzepatide became the benchmark compound in metabolic research.
Research-Grade Tirzepatide: What to Look For
When sourcing Tirzepatide for laboratory research, quality documentation is one of the most important considerations. Researchers should avoid suppliers that cannot provide clear testing information or transparent research-use-only product labelling.
A reliable Tirzepatide supplier should provide:
- Third-party Certificate of Analysis documentation
- Verified purity information
- Clear product labelling
- Lyophilised powder format
- Transparent research-use-only disclaimers
- Reliable domestic dispatch within Australia
Omega Peptides Australia supplies Tirzepatide for laboratory research in lyophilised powder format with accessible quality documentation, alongside the full buy peptides Australia range.
Lyophilised Tirzepatide and Research Preparation
Tirzepatide is commonly supplied in lyophilised powder form. Lyophilisation is a freeze-drying process used to support compound stability during storage and transport. This is especially important in Australia, where temperature conditions can vary significantly across different states and seasons.
For laboratory preparation, researchers may require a suitable sterile diluent depending on the protocol being followed. Omega Peptides Australia also supplies BAC Water for research preparation requirements.
Storage Considerations for Tirzepatide
Proper storage is essential for maintaining compound integrity. Lyophilised Tirzepatide should be stored according to the supplier's product documentation and relevant laboratory handling requirements.
General research storage considerations:
- Keep lyophilised material sealed until required for research use
- Protect from unnecessary heat, moisture, and light exposure
- Use appropriate cold storage where required by protocol
- Record preparation dates and handling details
- Follow all relevant laboratory safety procedures
Tirzepatide in Australia
Tirzepatide is not available for research use through pharmacies or standard therapeutic channels in Australia. It may be supplied by specialist research compound suppliers strictly for laboratory research use only. You can buy Tirzepatide in Australia from Omega Peptides Australia with COA verification and fast domestic dispatch, or explore related compounds in the peptides Australia collection.
Australian researchers should prioritise suppliers that offer domestic dispatch, clear COA documentation, transparent business details, and research-use-only labelling.
Frequently Asked Questions
What is Tirzepatide?
Tirzepatide is an investigational synthetic peptide studied for its dual agonist activity across the GIP and GLP-1 receptors. It is also referred to as LY3298176.
What is the research half-life of Tirzepatide?
Tirzepatide has a long research half-life, reported at approximately 5 days, which is why it has been studied using once-weekly administration in research settings.
How is Tirzepatide dosed in studies?
Dosage is protocol-dependent. The published clinical program used weekly dose-escalation across 5mg, 10mg and 15mg study arms. Tirzepatide is supplied strictly for laboratory research use only.
What is the difference between Tirzepatide and Retatrutide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, while Retatrutide is a triple agonist that adds glucagon receptor activity. Retatrutide engages one additional pathway.
How does Tirzepatide compare to Semaglutide?
Semaglutide is a single GLP-1 receptor agonist, whereas Tirzepatide is a dual GIP and GLP-1 agonist. In the SURMOUNT-5 research trial, tirzepatide was associated with greater weight reduction than semaglutide over 72 weeks.
Is Tirzepatide the same as Mounjaro or Zepbound?
Mounjaro and Zepbound are therapeutic brand names for tirzepatide used outside Australia. The research compound supplied here is the same molecule (LY3298176), provided strictly for laboratory research use only.
Is Tirzepatide approved for human use in Australia?
The research compound supplied by Omega Peptides Australia is not approved for human or veterinary use in Australia. It is supplied strictly for laboratory research purposes only.
What format is Tirzepatide usually supplied in?
Research-grade Tirzepatide is commonly supplied as a lyophilised powder to support stability during storage and transport.
Where can Australian researchers source Tirzepatide?
Australian researchers can source Tirzepatide from specialist suppliers such as Omega Peptides Australia, where it is supplied strictly for laboratory research use only.
References
- Coskun T, et al. LY3298176, a novel long-acting GIP/GLP-1 co-agonist. Molecular Metabolism, 2018.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021;385(6):503-515.
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet, 2021;398(10295):143-155.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387(3):205-216.
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020.
- Zepbound (tirzepatide) superior weight loss vs semaglutide, SURMOUNT-5. New England Journal of Medicine, 2025.
Research-Grade Tirzepatide from Omega Peptides Australia
Omega Peptides Australia supplies Tirzepatide in lyophilised powder format for laboratory research purposes only, with quality documentation and domestic Australian dispatch.